Amelioration of bromobenzene hepatotoxicity by Withania somnifera pretreatment: Role of mitochondrial oxidative stress  by Vedi, Mahima et al.
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a  b  s  t  r  a  c  t
The  present  study  investigated  the  possible  protective  role  of  Withania  somnifera  (Linn.)
Dunal  (Solanaceae)  root  powder  against  bromobenzene-induced  oxidative  damage  in  rat
liver mitochondria.  Administration  of  bromobenzene  (10  mmol/kg  body  weight)  to  rats
resulted  in  increased  levels  of  liver marker  enzymes,  lipid  peroxidation,  TNF-, IL-1
and  VEGF.  There  was  also  marked  depletion  in the  levels  of mitochondrial  enzymes  and
antioxidant  activity.  Pre-treatment  with  W.  somnifera  signiﬁcantly  decreased  the  levels
of liver  marker  enzymes,  TNF-,  IL-1, VEGF  and  ameliorated  histopathological  manifes-
tations  in bromobenzene-treated  rats.  The  molecular  docking  analysis  predicted  that the
pro-inﬂammatory  mediator  NF-B  showed  signiﬁcant  interaction  with  selected  various
active  components  of  W.  somnifera  (withaferin  A, withanolide  D  and  withanolide  E). Thiseywords:
ntioxidant
ipid  peroxidation
lutathione
romobenzene
xidative stress
study  demonstrates  a good  protective  effect  of  W. somnifera  against  bromobenzene-induced
oxidative  stress.
© 2014  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Bromobenzene (C6H5Br) is a well-known organic sol-
ent  and has profound use in the manufacture of various
rugs and chemicals. It is metabolized in the liver by
rimary cytochrome enzymes to form various oxides
f  bromobenzene, of which bromobenzene-3, 4-oxide is
Abbreviations: BB, Bromobenzene; GSH, reduced glutathione; SOD,
uperoxide dismutase; CAT, catalase; GPx, glutathione peroxidase; GST,
lutathione-s-transferase; WS,  Withania somnifera; ROS, reactive oxygen
pecies.
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214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
http://creativecommons.org/licenses/by-nc-nd/3.0/).highly reactive. Bromobenzene-3, 4-oxide is sequestered
by binding with reduced glutathione (GSH) and subse-
quently depleting hepatic glutathione levels. This results
in  reduced protection against intracellular reactive oxygen
species  (ROS) leading to secondary events such as mito-
chondrial dysfunction, changes in membrane permeability
and oxidative stress [1]. Mitochondria is a vital site for
energy metabolism and ATP production. Hence, its mal-
function leads to cellular damage and contributes to a
wide  range of diseases [2]. It can be suggested that mito-
chondrial dysfunction would be diminished by enriching
the  mitochondria with antioxidants, thereby reducing the
oxidative  stress.
Recent  studies have focussed on the potential of various
natural compounds against liver pathological conditions.
Silymarin and N-acetyl-L-cysteine are being already used
is is an open access article under the CC BY-NC-ND license
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Table 1
Experimental animal design for the study.
Groups Treatment
Group I Normal control (received single dose of 0.1 ml
coconut  oil through intragastric intubation once
and  sacriﬁced after 19 h)
Group  II Bromobenzene (10 mmol in 0.1 ml coconut oil by
intragastric intubation) once and sacriﬁced after
19  h
Group III Withania somnifera (250 mg/kg, orally) for 8 days
and  a single dose of bromobenzene (10 mmol/kg in
0.1 ml  coconut oil, intragastric intubation) on the
8th day and sacriﬁced after 19 h
Group IV Withania somnifera (500 mg/kg, orally) for 8 days
and  a single dose of bromobenzene (10 mmol/kg in
0.1 ml  coconut oil, intragastric intubation) on the
8th day and sacriﬁced after 19 h
Group V silymarin (100 mg/kg, orally) for 8 days and a
single  dose of bromobenzene (10 mmol/kg in
0.1  ml  coconut oil intragastric intubation) on the630 M. Vedi et al. / Toxicol
in the clinical treatment of liver injury and they exhibit
a  potent hepatoprotective activity, but with certain limita-
tions  such as gastric irritation, allergies and limited efﬁcacy
[3,4].  This indicates that there is still the need of ﬁnding
highly effective and reliable drugs with minimal side effects
for  the prevention of acute liver failure.
Withania somnifera (Linn.) Dunal (Solanaceae) is a
well-known Ayurvedic medicine known to possess phar-
macological properties such as antistress, antioxidant,
immunomodulating and anti-arthritic activities [5,6].
These  properties may  be due to the presence of various
biologically active chemical constituents such as alkaloids
(isopellertierine, anferine), steroidal lactones (withano-
lides, withaferins), saponins containing an additional acyl
group  (sitoindoside VII and VIII), and withanoloides with a
glucose  at carbon 27 (sitonidoside XI and X) [7,8]. The roots
of  W.  somnifera are the most pharmacologically active part
of  the plant and are known to possess free radical scaveng-
ing  and antioxidant activity [9]. Therefore, an attempt was
made  to evaluate the hepatoprotective effect of W.  som-
nifera  root powder against bromobenzene-induced acute
liver  necrosis which has not been reported to the best of our
knowledge. Silymarin has been used as the standard refer-
ence  drug in the present study. Also, the effect of selected
active components of W.  somnifera on NF-B was  analyzed
using molecular docking.
2.  Materials and methods
2.1.  Animals
Wistar albino rats of either sex, weighing 120–150 g
were  obtained from animal house, VIT University, Vellore.
They  were fed with commercial pelleted feed from Hin-
dustan  Lever Ltd. (Mumbai, India) and water ad libitum.
The  animals were maintained according to the guidelines
recommended by the Committee for the Purpose of Super-
vision  and Control of Experiments on Animals (CPSCEA),
Government of India, Chennai, Tamil Nadu. Experimental
procedure for the present study has been approved by the
ethical  committee (VIT/IAEC/VIIth/17) of VIT University,
Vellore, India.
2.2.  Drugs and chemicals
Commercially available W.  somnifera root powder was
obtained from Indian Medical Practitioners Co-operative
Stores and Society (IMCOPS, Chennai, India). Silymarin, a
standard  hepatoprotective drug, was obtained from Micro
Labs  Ltd (Goa, India). All other reagents used were standard
laboratory reagents of analytical grade and were purchased
locally. The effective dosage of bromobenzene [10] and W.
somnifera  [11] were based on the basis of previous studies.
Aqueous suspension of silymarin (100 mg/kg body weight)
and  W.  somnifera (250 and 500 mg/kg body weight) were
made  in double distilled water for administration to rats.3.  Experimental procedure
Animals  were allocated randomly in six groups of six
animals each. In this study, all group of rats except group8th  day and sacriﬁced after 19 h
Group VI Withania somnifera (500 mg/kg, orally) for 8 days
and  sacriﬁced after 19 h
I and group VI received bromobenzene dosage (intragas-
tric tube) only once. The animals were treated as shown in
Table  1:
All  six groups were fasted for 24 h before and
19 h after the administration of silymarin/W. som-
nifera/bromobenzene/coconut oil. After the collection
of blood, samples from liver tissues (approximately
0.05–0.1 g) were homogenized in phosphate buffer (pH 7.4)
to  give 20% w/v  homogenate [12]. This homogenate was
centrifuged at 3000 g and 4 ◦C for 10 min; the supernatant
was  stored at −20 ◦C until analysis.
3.1.  Serum biochemical parameters, antioxidant status,
plasma ceruloplasmin and total sulfhydryl group
determination
The activities of aspartate aminotransferase (AST), alka-
line  aminotransferase (ALT), alkaline phosphatase (ALP),
albumin, total bilirubin and direct bilirubin were deter-
mined according to the manufacturer’s protocol using kits
(Autospan diagnostics, Bangalore, India) in the serum of
control  and experimental rats.
Antioxidant status was  determined in the plasma and
liver  tissue of control as well as experimental rats. Lipid
peroxidation was determined by the procedure of Ohkawa
et  al. [13] and malondialdehyde (MDA), which forms as end
product  of lipid peroxidation, was  measured. Superoxide
dismutase (SOD), catalase (CAT), glutathione peroxidase
(GPx), glutathione-s-transferase (GST) and reduced glu-
tathione  were also evaluated [14–18]. Total protein was
estimated according to the method of Lowry et al. [19] using
bovine  serum albumin as standard. Furthermore, plasma
ceruloplasmin [20] and total sulfhydryl groups [21] were
measured in plasma and liver respectively in the control
and  experimental rats.3.2.  Isolation of mitochondria
For  the isolation of liver mitochondria, the method
of Johnson and Lardy [22] was  followed and the protein
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ontent was measured according to manufacturer’s
rotocol using kit obtained from Autospan diagnostics,
angalore, India.
.3.  Evaluation of mitochondrial enzymes
Isocitrate dehydrogenase activity was measured using a
alibration  curve with -ketoglutarate as standard and was
xpressed as nmol of -ketoglutarate formed/h/mg pro-
ein  [23]. The activity of -ketoglutarate dehydrogenase
as assayed by the method of Reed and Mukherjee [24]
nd  the reaction was terminated by the addition of tricar-
oxylic acid (TCA). The colour developed was measured at
40  nm.  A standard containing potassium ferrocyanide was
ssayed  simultaneously. The activity of succinate dehy-
rogenase was  assayed according to the method of Slater
nd  Bonner [25] using sodium succinate and potassium
erricyanide, and the change in optical density (OD) was
ecorded at 15 s intervals for 5 min  at 420 nm.  Succinate
ehydrogenase activity was expressed as nmol of suc-
inate  oxidized/min/mg protein. The activity of malate
ehydrogenase was assayed by the method of Mehler
t  al. [26]. Reaction mixture containing phosphate buffer,
ADH,  oxaloacetate and mitochondrial suspension was
repared. The change in OD at 340 nm was measured for
 min  at intervals of 15 s in a UV spectrophotometer. The
ctivity of the enzyme was expressed as nmol of NADH oxi-
ized/min/mg protein. The activity of cytochrome c oxidase
as  assayed according to the method of Pearl et al. [27] and
he  change in absorbance was recorded at 550 nm for 5 min
t  intervals of 15 s. The enzyme activity was expressed as
hange  in absorbance/min/mg protein. The enzyme activ-
ty  of NADH dehydrogenase was assayed by the method of
inakami  et al. [28] and was expressed as nmol of NADH
xidized/min/mg protein.
.4.  Measurement of serum TNF-˛, IL1  ˇ and VEGF
The serum concentrations of TNF-, IL1 and VEGF were
easured by ELISA according to manufacturer’s protocol
sing commercial kits (Krishgen BioSystems, Bangalore,
ndia) and were expressed in nanograms per millilitre.
.5. Docking study of active components of W.  somnifera
ith NF-B
A  three dimensional structure of the binding
omain of NF-B (PDB ID: 3U21) was downloaded
able 2
ffect of the administration of bromobenzene on liver weight with or without pri
Groups L
Group I (Control) 5
Group II (Bromobenzene-10 mmol/kg) 6
Group III (Withania somnifera-250 mg/kg +Bromobenzene-10 mmol/kg) 5
Group IV (Withania somnifera-500 mg/kg + Bromobenzene-10 mmol/kg) 5
Group V (Silymarin-100 mg/kg + Bromobenzene-10 mmol/kg) 4
Group VI (Withania somnifera -500 mg/kg) 5
ach value represents the mean ± SD of six rats. Comparisons were made as follo
tatistical  analysis was calculated by one way  analysis of variance (ANOVA) follow
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using the protein databank database (http://www.rcsb.
org/pdb/home.do) (Fig. 4). The sequences of selected
active components of W.  somnifera such as with-
aferin A, withanolide D and withanolide E were
obtained from pubchem (http://www.ncbi.mlm.nih.gov.
pccompound) and submitted in SMILES format on Corina
(http://www.molecular-networks.com/node/84) to gen-
erate 3-Dimensional structures of the ligands (Fig. 4).
Docking was done using PatchDock server and the scoring
in  PatchDock is based on both geometric ﬁt and atomic
desolvation energies.
3.6.  Histopathological studies
Immediately after sacriﬁce, a portion of the liver was
ﬁxed in 10% formalin, then washed, dehydrated in descen-
ding  grades of isopropanol and ﬁnally rinsed with xylene.
The  tissues were then embedded in molten parafﬁn wax.
Sections were cut at 5 mm thickness, stained with haema-
toxylin and eosin and were observed microscopically for
histopathological changes (400× magniﬁcation).
3.7. Statistical analysis
All  results were expressed as mean ± SD compared to
normal control rats. The intergroup variation between
various groups was measured by one way  analysis of vari-
ance  (ANOVA) and the comparisons between the groups
were  conducted by Student Newman–Keul’s test using
the  software Graph Pad InStat version 3.10. Results were
considered statistically signiﬁcant when *p < 0.05. Compar-
isons  were made as follows: a-group I vs groups II–VI;
b-group II vs group III–VI.
4.  Results
4.1. Effects of W.  somnifera on liver weight and serum
biochemical parameters
The  results observed in groups which were pre-treated
with W.  somnifera and silymarin with respect to the induc-
tion  of hepatotoxicity using bromobenzene are given in
Table  2 and 3. Rats which were treated with bromoben-
zene developed liver damage as evidenced by increase in
the  activities of liver functional markers; ALT, AST, ALP,
total  and direct bilirubin (Table 3). Moreover, there was
an  increase in the liver weight and decrease in the albu-
min  levels in bromobenzene treated group as compared
to the control group of rats (Table 2). W.  somnifera (250
or administration of Withania somnifera in control and experimental rats.
iver weight (g) Body weight initial (g) Body weight before
sacriﬁce  (g)
.19 ± 0.55 118.32 ± 13.20 122.17 ± 14.30
.27 ± 0.27a* 117.17 ± 15.31 120.50 ± 12.07
.38 ± 0.18b* 119.05 ± 8.15 125.16 ± 11.09
.16 ± 0.13b* 118.00 ± 15.33 129.50 ± 13.41
.86 ± 0.26b* 116.33 ± 14.70 119.36 ± 12.80
.47 ± 0.36b* 120.75 ± 10.90 129.87 ± 14.97
ws: a-group I vs groups II, III, IV, V, VI; b− group II vs group III, IV, V, VI.
ed by the Student Newman–Keul’s test.
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Table  3
Effect  of the administration of bromobenzene (BB) on levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase
(ALP),  albumin, direct and total bilirubin with or without prior administration of Withania somnifera (WS) in serum of control and experimental rats.
Parameters Group I (Control) Group II (BB –
10  mmol/kg)
Group III (WS  -
250  mg/kg + BB)
Group IV (WS  –
500  mg/kg + BB)
Group V (Silymarin
–  100 mg/kg + BB)
Group VI (WS  –
500  mg/kg)
AST (U/L) 114.04 ± 0.73 236.07 ± 1.15a* 145.1 ± 0.52a*b* 134.45 ± 3.58a*b* 136.26 ± 3.01a*b* 128.14 ± 1.63b*
ALT(U/L) 48.44 ± 3.12 113.09 ± 1.65 a* 57.13 ± 1.67 b* 55.25 ± 2.51 a*b* 57.68 ± 2.32 b* 54.41 ± 1.77 b*
ALP(U/L) 87.04 ± 3.08 167.88 ± 9.95 a* 113.04 ± 3.16 a*b* 106.02 ± 6.70 a*b* 135.01 ± 2.91 a*b* 103.60 ± 7.61 b*
Total Bilirubin
(mg/dl)
0.88 ± 0.07 3.29 ± 0.48a* 2.40 ± 0.23a*b* 1.28 ± 0.08b* 1.51 ± 0.09a*b* 1.01 ± 0.03b*
Direct Bilirubin
(mg/dl)
0.03 ± 0.01 0.36 ± 0.05 a* 0.19 ± 0.01 a*b* 0.12 ± 0.01 a*b* 0.15 ± 0.02 a*b* 0.04 ± 0.01 b*
Albumin (g/l) 42.52 ± 1.44 35.38 ± 1.62a* 41.36 ± 1.38 44.80 ± 1.60b* 48.15 ± 0.54b* 42.18 ± 0.21b*
e as foll
A) folloEach value represents the mean ± SD of six rats. Comparisons were mad
Statistical  analysis was  calculated by one way  analysis of variance (ANOV
* The symbols represent statistical signiﬁcance at p < 0.05.
and 500 mg/kg) pre-treatment restored the levels of ALT,
AST,  ALP, total bilirubin, direct bilirubin and albumin in
bromobenzene treated group of rats.4.2. Effect of W.  somnifera on antioxidant levels
Malondialdehyde (MDA) is the main oxidative degra-
dation product during lipid peroxidation and functions
Table 4
Effect  of the administration of bromobenzene (BB) on antioxidant status, lipid p
without  prior administration of Withania somnifera (WS) in plasma and liver tissu
Parameters Group I (Control) Group II (BB –
10  mmol/kg)
Group III
250  mg/k
Liver
Catalase
(Units/min/mg
protein)
64.05  ± 0.93 21.57 ± 0.30a* 31.94 ± 
SOD (U/mg protein) 68.85 ± 7.06 23.85 ± 2.07a* 43.90 ± 
Lipid Peroxidation
(nmol/mg protein)
1.44 ± 0.03 3.25 ± 0.09a* 1.53 ± 
GST (nmol/minmg
protein)
19.97  ± 0.10 7.65 ± 0.14a* 15.94 ± 
Reduced Glutathione
(mmol/mg protein)
7.95  ± 0.21 3.33. ± 0.67a* 8.27 ± 
Glutathione  Peroxidase
(g  of GSH
utilized/min/mg
protein)
26.42  ± 3.85 16.5 ± 1.93a* 24.40 ± 
Total Sulfhydryl groups
(nmol/mg  protein)
18.5 ± 3.08 7.08 ± 0.79a* 12.23 ± 
Plasma
Catalase
(Units/min/mg
protein)
62.99  ± 6.85 43.55 ± 1.45a* 55.32 ± 
SOD (U/mg protein) 52.60 ± 7.77 24.50 ± 2.73a* 42.4 ± 
Lipid  Peroxidation
(nmol/mg protein)
3.04  ± 0.12 6.18 ± 0.82a* 4.16 ± 
GST  (nmol/min mg
protein)
16.63 ± 2.36 8.41 ± 2.92a* 14.78 ± 
Reduced Glutathione
(mmol/mg protein)
15.86 ± 0.38 7.65 ± 0.67a* 12.89 ± 
Glutathione Peroxidase
(g  of GSH
utilized/min/mg
protein)
29.16  ± 3.17 18.58 ± 2.92a* 27.12 ± 
Plasma  ceruloplasmin
(g/l)
0.75  ± 0.08 1.89 ± 0.62a* 0.94 ± 
Each value represents the mean ± SD of six rats. Comparisons were made as follo
Statistical  analysis was  calculated by one way  analysis of variance (ANOVA) follo
* The symbols represent statistical signiﬁcance at p < 0.05.ows: a-group I vs groups II, III, IV, V, VI; b-group II vs group III, IV, V, VI.
wed by the Student Newman–Keul’s test.
as  a marker of oxidative injury to cellular membranes.
Antioxidant status was found to be depleted (Table 4)
accompanied with an increase in the levels of MDA  in both
plasma  and hepatic tissue of bromobenzene-treated group
as  compared to the control group. Levels of CAT, SOD and
glutathione were signiﬁcantly enhanced, whereas levels of
MDA  were reduced in W.  somnifera and silymarin treated
groups. The highest dose (500 mg/kg) of W.  somnifera
eroxidation, plasma ceruloplasmin and total sulfhydryl groups with or
e homogenate of control and experimental rats.
 (WS  –
g + BB)
Group IV (WS  –
500  mg/kg + BB)
Group V
(Silymarin –
100  mg/kg + BB)
Group VI  (WS  –
500  mg/kg)
1.52b* 60.18 ± 7.09b* 59.4 ± 8.47a*b* 61.84 ± 2.08b*
4.82a*b* 66.9 ± 7.84b* 63.5 ± 7.12b* 66.42 ± 7.83b*
0.03b* 1.50 ± 0.06b* 1.51 ± 0.04b* 1.56 ± 0.02b*
0.15a*b* 19.43 ± 0.31b* 19.12 ± 0.16b* 19.57 ± 0.17b*
0.12b* 7.93 ± 0.47 8.25 ± 0.49 7.68 ± 0.12
3.02b* 25.70 ± 2.20b* 25.08 ± 1.16b* 25.76 ± 4.03b*
1.52a*b* 15.16 ± 1.60b* 13.50 ± 2.88a*b* 17.83 ± 2.31
3.59 59.68 ± 1.75b* 56.13 ± 2.83 60.8 ± 3.02a*
4.49b* 50.21 ± 4.12a* 42.35 ± 10.46b* 51.28 ± 5.47
0.17a* 3.60 ± 0.31b* 3.72 ± 0.71b* 3.83 ± 0.26
0.17 15.27 ± 0.18a* 15.22 ± 0.11b* 16.32 ± 0.14b*
1.94a* 13.26 ± 2.01 10.43 ± 1.45a* 14.69 ± 0.27a*
2.24 23.42 ± 1.94b* 28.94 ± 2.11 28.32 ± 1.23
0.07 0.77 ± 0.12 0.89 ± 0.10 0.78 ± 0.44
ws: a-group I vs groups II, III, IV, V, VI; b− group II vs group III, IV, V, VI.
wed by the Student Newman–Keul’s test.
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Table 5
Effect of the administration of bromobenzene with or without the prior administration of Withania somnifera or silymarin on mitochondrial enzymes in
liver  of control and experimental rats.
Parameters Group I (Control) Group II (BB –
10  mmol/kg)
Group III (WS  –
250  mg/kg + BB)
Group IV (WS  –
500  mg/kg + BB)
Group V (Silymarin
–  100 mg/kg + BB)
Group VI (WS  –
500  mg/kg)
Isocitrate
dehydrogenase
(UA/mg  protein)
404.11 ± 9.60 293.14 ± 11.01a* 348.13 ± 10.78a*b* 391.93 ± 10.34b* 374.62 ± 10.17a*b* 397.07 ± 11.82b*
-Ketoglutarate
dehydrogenase
(UB/mg  protein)
99.93  ± 8.71 59.12 ± 6.92a* 89.53 ± 4.31a*b* 94.10 ± 10.52a*b* 85.08 ± 10.13a*b* 98.94 ± 1.95b*
Succinate
dehydrogenase
(UC/mg  protein)
46.12 ± 2.52 18.21 ± 1.78a* 34.12 ± 2.53a*b* 39.94 ± 2.56b* 31.45 ± 1.93a*b* 45.11 ± 1.46 b*
Malate
dehydrogenase
(UD/mg  protein)
283.52 ± 16.53 174.22 ± 19.24a* 220.83 ± 18.53a*b* 263.12 ± 10.41a*b* 253.14 ± 7.28a*b* 278.14 ± 9.53 b*
NADH
dehydrogenase
(UE/mg  protein)
46.24 ± 4.62 19.93 ± 3.46a* 31.56 ± 2.93a*b* 38.43 ± 3.48b* 31.57 ± 8.34a*b* 42.14 ± 3.23b*
Cytochrome-c-
oxidase (UF/mg
protein)
12.43 ± 1.47 3.53 ± 1.45a* 5.31 ± 1.97a*b* 9.25 ± 1.32b* 8.57 ± 1.20 a*b* 11.92 ± 2.04b*
Each value represents the mean ± SD of six rats. Comparisons were made as follows: a− group I vs groups II, III, IV, V, VI; b− group II vs group III, IV, V,
VI.  UA, nmol of a-ketoglutarate formed/h; UB, nmol of ferrocyanide formed/h; UC, nmol of succinate oxidized/min; UD, nmol of NADH oxidized/min; UE,
n nalysis w
S
s
e
4
a
w
b
g
F
e
g
Nmol  of NADH oxidized/min; UF, change in OD 9 10–2 min–1. Statistical a
tudent  Newman–Keul’s test.
* The symbols represent statistical signiﬁcance at p < 0.05.
howed maximum recovery of antioxidant activities in the
xperimental animals.
.3.  Effects of W.  somnifera on total sulfhydryl groups
nd plasma ceruloplasmin contentTable 4 shows increased plasma ceruloplasmin levels
hile there was depletion in the total sulfhydryl levels in
romobenzene treated group in comparison to the control
roup  of rats. Pre-administration of W.  somnifera restored
ig. 1. Effect of the administration of bromobenzene on serum levels of TNF- w
xperimental  rats. Each value represents the mean ± SD of six rats. Comparisons
roup  III, IV, V, VI. The symbols represent statistical signiﬁcance at *p < 0.05. Statis
ewman–Keul’s  test.as  calculated by one way analysis of variance (ANOVA) followed by the
the  levels of plasma ceruloplasmin and total sulfhydryl
groups to near normal levels.
4.4. Effect of W.  somnifera on mitochondrial enzymes
The activities of TCA cycle enzymes (Isocitrate dehy-
drogenase, -ketoglutarate dehydrogenase, succinate
dehydrogenase, malate dehydrogenase) and respiratory
enzymes (NADH dehydrogenase and cytochrome c oxi-
dase)  were found to be signiﬁcantly reduced (p < 0.05)
ith or without prior administration of Withania somnifera in control and
 were made as follows: a-group I vs groups II, III, IV, V, VI; b-group II vs
tical analysis was  calculated by one-way ANOVA followed by the Student
634 M. Vedi et al. / Toxicology Reports 1 (2014) 629–638
Fig. 2. Effect of the administration of bromobenzene on serum levels of IL1 with or without prior administration of Withania somnifera in control and
arisons
5. Statisexperimental  rats. Each value represents the mean ± SD of six rats. Comp
group  III, IV, V, VI. The symbols represent statistical signiﬁcance at *p < 0.0
Newman–Keul’s  test.
due to the administration of bromobenzene to rats. W.
somnifera (250 and 500 mg/kg) or silymarin pre-treatment
restored the activities of mitochondrial enzymes and
brought them to near normal levels (Table 5).
4.5. Measurement of serum TNF-˛, IL1  ˇ and VEGF
It is already known that pro-inﬂammatory cytokines
(TNF- and IL1) and signal protein (VEGF) promote oxida-
tive  stress, therefore, their concentration in serum was
found  to be signiﬁcantly enhanced in the bromobenzene
alone treated group (Figs. 1–3). Prior administration of W.
somnifera  (250 and 500 mg/kg) and silymarin prevented the
increase  in serum concentrations of TNF-, IL1 and VEGF.4.6.  Docking analysis
The  molecular docking analyses showed that there was
a  strong interaction between selected active components of
Fig. 3. Effect of the administration of bromobenzene on serum levels of VEGF w
experimental  rats. Each value represents the mean ± SD of six rats. Comparisons
group  III, IV, V, VI. The symbols represent statistical signiﬁcance at *p < 0.05. Statis
Newman–Keul’s  test. were made as follows: a-group I vs groups II, III, IV, V, VI; b- group II vs
tical analysis was calculated by one-way ANOVA followed by the Student
W.  somnifera i.e., Withanolide D, Withanolide E and With-
aferin  A with NF-B. Due to these interactions, the selected
active components of W.  somnifera block normal pathway
of  NF-B for release of inﬂammatory mediators (Fig. 4 and
Table  6).
4.7.  Histopathological examination of liver damage
The light microscopy examination of the representative
sections of control rat liver clearly shows complete hepatic
lobules with distinct hepatic cells. Hepatic cells were
arranged in cord like fashion, which were separated by
sinusoids and central vein was clearly visible (Fig. 5a) and
the  liver sections of bromobenzene treated rats showed
massive fatty changes (Fig. 5b). Pre-treatment with W.
somnifera (250 and 500 mg/kg) was  effective in restoring
the  bromobenzene-induced histopathological lesions,
however highest dose was found to be more effective
(Fig. 5c and d). The histological architecture of liver
ith or without prior administration of Withania somnifera in control and
 were made as follows: a-group I vs groups II, III, IV, V, VI; b-group II vs
tical analysis was calculated by one-way ANOVA followed by the Student
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F en) (b) 
r  version
s
c
(
5
n
T
Dig. 4. Molecular docking of Withanolide E (purple) (a), Withaferin A (gre
eferences  to color in this ﬁgure legend, the reader is referred to the web
ections of rats that received silymarin showed absence of
ell  necrosis, but with minimal inﬂammatory conditions
Fig. 5e). In case of administration of W.  somnifera at
00  mg/kg dose, the micrographs exhibited an almost
ormal architecture (Fig. 1f).
able 6
ocking studies of active components of Withania somnifera (Withaferin A, Witha
Active component Atomic contact
energy (ACE)
Docking score 
Withaferin A −234.51 5120 
Withanolide D −232.17 5520 
Withanolide E −205.70 5378 and Withanolide D (blue) (c) with NF-kB (Red). (For interpretation of the
 of the article.)
5. DiscussionBromobenzene is subjected to biotransformation in the
liver  by cytochrome P450 enzymes to form highly hepato-
toxic  metabolites [29]. It is known to cause functional and
nolide D and Withanolide E) with pro-inﬂammatory mediator NF-kB.
No. of hydrogen
(H)  bonds
Residues involved Length of the H
bond
1 Leu-H62 1.3 A◦
1 Ile-H63 2.7 A◦
1 Asn-O33 3.0 A◦
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ntrol), 
/kg + br
under 4Fig. 5. Histopathological monograph of the liver. (a) Group I (Co
250  mg/kg + bromobenzene), (d) Group IV (Withania somnifera – 500 mg
(e)  Group VI (Withania somnifera – 500 mg/kg), all the pictures are taken 
morphological alterations in the liver cell membrane, as
evidenced by increase in AST, ALT and ALP, which were in
accordance with the previous studies [30]. Pre-treatment
with W.  somnifera depicted its protective action against
cellular injury and normalized the levels of AST, ALT and
ALP,  which may  be due to its membrane stabilizing action
(Table  3). A high concentration of bilirubin in serum is an
indication for increased erythrocyte degeneration rate. W.
somnifera  helped in decreasing the signiﬁcantly (p < 0.05)
altered  levels of total and direct bilirubin, thus bringing
liver to normal functionality (Table 3).(b) Group II (bromobenzene), (c) Group III (Withania somnifera –
omobenzene), (e) Group V (Silymarin 100 mg/kg+ bromobenzene), and
00× magniﬁcation.
It is known that BB-3,4 oxide causes glutathione deple-
tion,  therefore, a decrease of the general cellular red/ox
balance will automatically increase the ROS level (there
are  other sources to ROS than a damaged mitochondrion).
Furthermore, BB metabolites such as bromobenzene phe-
nols  can be oxidized to hydroquinones, which also may
form  ROS. Intragastric intubation of bromobenzene at
10  mmol/kg in 19 h elicited a signiﬁcant alteration of some
antioxidant mechanisms and drug metabolizing enzymes
in  the liver [2,31]. Pre-treatment with W.  somnifera at
both  doses caused marked elevation in the levels of these
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ntioxidants which may  be associated with its free rad-
cal  scavenging and antioxidant enhancing abilities as
eported in previous studies. Furthermore, reduction in
otal  sulfhydryl groups possibly means that these might
ave  been used to combat the action of toxic by-products
ormed from bromobenzene metabolism [32]. Plasma ceru-
oplasmin  levels were also increased due to acute phase
esponse [33] in bromobenzene treated rats. The active
omponents of W.  somnifera probably react directly with
nd  detoxify the reactive electrophilic bromobenzene (BB)
etabolite  BB-3,4-oxide, as well as possible ROS molecules
ormed. Furthermore, the ROS molecules can be secondary
o  damage mitochondrion as suggested, but the mitochon-
rial  damage may  not be the only source for ROS. Also,
here was a decrease in the activities of liver mitochon-
rial enzymes due to the administration of bromobenzene
o rats and W.  somnifera pre-treatment prevented the
ecrease in their levels, which is in concordance with the
revious  studies [34].
Reactive  oxygen species promote inﬂammation by
nhancing the activation of transcription factor NF-B,
hich controls the formation of cytokines, chemokines,
nd adhesion molecules [35,36]. In the present study,
hrough docking analysis it was shown that some selected
ctive components of W.  somnifera show signiﬁcant inter-
ctions  with NF-B. Also, in rats which were treated with
romobenzene only, levels of TNF-, IL1 and VEGF were
ound to be elevated as a result of inﬂammation (Figs. 1–3).
rior  administration of W.  somnifera was able to reduce
heir levels in serum in a dose dependent manner. Thus,
t  can be suggested that W.  somnifera is able to counter-
ct bromobenzene-induced hepatotoxicity and oxidative
tress due to the presence of its active components by inter-
cting  with the inﬂammatory mediator, NF-B (Fig. 4).
The  hepatoprotective effect was supported by the
iver histological changes produced by W.  somnifera as
ompared to the control and bromobenzene treated
ats. W.  somnifera pre-treatment markedly attenuated
he bromobenzene-induced liver cell necrosis in a dose
ependent manner and restored more or less the same
istopathological picture as observed in the control group
Fig.  5c and d).
.  Conclusion
It  can be concluded from this study that the roots of
.  somnifera offer signiﬁcant dose-dependent protection
gainst bromobenzene-induced liver injury to rats and
he  hepatoprotective effect was comparable to silymarin,
hich is the standard drug of reference for hepatopro-
ection. Moreover, results obtained in this study support
he  antioxidant properties of W.  somnifera [34]. However,
urther pharmacological evidence supporting the role of
.  somnifera against bromobenzene-induced liver injury
s  needed and more studies are required to explore the
echanisms for the same.onﬂict  of interests
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